Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0020

Advisory board · Dr. Daniel Weber

10 May 2026 · In person · Dr. Daniel Weber, Johns Hopkins · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0020—

Capture insight from this engagement

Location: Johns Hopkins
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line
Infusion-reaction management

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Advisory board with thoracic medical oncologist at Johns Hopkins. Discussed chemotherapy-free first line, infusion-reaction management.

Insights captured (1)

Capture insight

INS-0072Medium
Chemotherapy-free first line
Chemotherapy-free first line: interest in collaboration reported by thoracic medical oncologist (US).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 2
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0020

Audit history (0)

All create, update and approval events for this record

No audit events in sample data